Gilenya (fingolimod) Capsules
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
February 2016
CONTRAINDICATIONS
Patients who have had a hypersensitivity reaction to fingolimod or any of the excipients...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Gilenya